UBS Group
BLTE

UBS Group’s Belite Bio BLTE Stock Holding History

UBS Group’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123M Buy
768,359
+639,607
+497% +$108M 0.02% 903
2025
Q4 		$20.6M Buy
128,752
+117,418
+1,036% +$13.9M ﹤0.01% 2566
2025
Q3 		$839K Buy
11,334
+8,976
+381% +$589K ﹤0.01% 5712
2025
Q2 		$136K Buy
2,358
+1,807
+328% +$110K ﹤0.01% 6987
2025
Q1 		$36.5K Sell
551
-11,656
-95% -$702K ﹤0.01% 7819
2024
Q4 		$770K Buy
12,207
+12,079
+9,437% +$796K ﹤0.01% 5517
2024
Q3 		$6K Buy
+128
New +$6.2K ﹤0.01% 8004
2024
Q1 		– Sell
-348
Closed -$15.9K – 9328
2023
Q4 		$15.9K Sell
348
-535
-61% -$20.6K ﹤0.01% 7237
2023
Q3 		$28.1K Buy
883
+583
+194% +$14.6K ﹤0.01% 6619
2023
Q2 		$4.29K Buy
300
+180
+150% +$4.09K ﹤0.01% 7550
2023
Q1 		$3.59K Sell
120
-4,097
-97% -$125K ﹤0.01% 8297
2022
Q4 		$127K Buy
+4,217
New +$124K ﹤0.01% 5879
2022
Q3 		– Sell
-683
Closed -$21K – 10340
2022
Q2 		$21K Buy
+683
New +$12.8K ﹤0.01% 6798

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS Group's BLTE Position: Q1 2026 in Review

UBS Group increased its Belite Bio (BLTE) stake by 497% in Q1 2026, buying an estimated $108M and bringing the position to 768,359 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #903.

UBS Group first reported a position in BLTE in Q2 2022 and has held it in 13 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • UBS Group held 768,359 shares of Belite Bio worth $123M as of Q1 2026.
  • UBS Group bought 639,607 Belite Bio shares in Q1 2026, an estimated $108M.
  • Belite Bio made up 0.02% of UBS Group's portfolio in Q1 2026, its #903 holding.
  • UBS Group first reported a position in Belite Bio in Q2 2022 and has held it in 13 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.